Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? - Wikidata - awgldk - TriplyDB

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

http://www.wikidata.org/entity/Q38125770

about

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion Dilemma of first line regimens in metastatic pancreatic adenocarcinoma Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.Nucleoside analogs: ready to enter the era of precision medicine?Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization.Future role of endoscopic ultrasound in personalized management of pancreatic cancer.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

P2860

Q24273350-9FFC7A48-B6BB-44F5-AA15-0974F7117FB1 Q28077147-3E365ED4-89AF-40B8-BC38-C8ED95462618 Q34067863-2E37D287-DDCB-458C-9EDC-D7FA47F26D5A Q35812824-B2FBBE08-8988-48B7-BD53-3279C8F5D92F Q36342657-6A521CE4-0D8F-4C30-B24D-FEC30BD5D869 Q37720259-3AADE681-9F85-4B48-8618-88C3B693129F Q38842938-7AF6FF7E-F2D7-445A-BA4A-72D993F2E036 Q41487497-31B452F9-A1C9-4E27-B63E-55B554A018E2 Q47128811-299EAAF4-DCCF-4B9B-8F60-F9F0333FCF7F Q47138141-1A1672AE-C813-4F1D-A316-762A34898B8F Q47830761-A7857D5E-7034-4A15-86B9-6E3896094FF9 Q55361920-B1B84A97-6C48-48A1-B2B2-C3AD51F0EC1D

P2860

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

http://www.wikidata.org/entity/Q38125770

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

@en

type

label

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

@en

prefLabel

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

@en

P1433

Q38125770-006E607F-8905-41CB-B187-2A5073D83EF0

P1476

Q38125770-8D40D8A9-C038-4CB4-8E16-3EB0D76C333E

P2093

Q38125770-07646106-B9EE-42CC-A1C3-0F862A0BA368

Q38125770-B5BE241E-4BEC-4E27-A398-47088D3BDE04

P2860

Q38125770-0FB94B71-10AD-4CB4-931E-66C5A6CFF6DB

Q38125770-162B2722-1CC9-4DC7-93C7-E9820E94E9D9

Q38125770-1C3ACD1A-56CD-4E98-8791-213283BBFFEE

Q38125770-1D946D74-9025-41CC-871D-BD2DAD437D75

Q38125770-1F99E866-91EE-4AC8-9948-72099AFC4754

Q38125770-1FA31A3E-634D-4016-B999-7952FC3B5F8A

Q38125770-2A5D6512-BEDE-44FB-80F2-FEEDEC64315C

Q38125770-37A798B7-B7A3-4D0B-8B2D-C555A33F7AB3

Q38125770-4801B8AC-DE2F-4F61-B679-022F5A75A214

Q38125770-509A08D1-3751-4334-80FB-9AD4111FE973

P304

Q38125770-AF74E392-EFAB-4C6A-B9EF-F7A04715DD7B

P31

Q38125770-1F3B0A74-1C50-4BA4-9468-2BB684A7A0C6

P356

Q38125770-4A2EEF2C-C0BA-4676-9053-4C5F06A2F02E

P433

Q38125770-71EEAF15-BD42-4824-B12C-2404B48BF80D

P478

Q38125770-2409299D-045E-4B5F-BAA7-DC3858025708

P50

Q38125770-70AEB31B-741C-46F7-BB46-508E27E1783D

Q38125770-E7BCCE1F-5B86-4059-ADDD-747D70E6B9AB

P577

Q38125770-3501A0DC-F0D1-4FA5-955A-4BEAAF762E47

P698

Q38125770-D6A4F9E6-9F2E-4423-8692-425FF82DC0B4

P356

P1433

Biomarkers in Medicine

P1476

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

@en

P2093

Charles Dumontet

http://www.w3.org/2001/XMLSchema#string

Lars Petter Jordheim

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies

The pancreas cancer microenvironment

Cancer statistics, 2012

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer.

P304

663-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/BMM.13.48

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23905902

http://www.w3.org/2001/XMLSchema#string